Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PrP Assay Correlates With Bioassay; WHO Calls For TSE Reference Materials

This article was originally published in The Gray Sheet

Executive Summary

Clearance of protease-resistant prion proteins (PrP-SC or PrP-RES) appears to correlate with clearance of transmissible spongiform encephalopathy (TSE) infection, Bayer pathogen safety researcher Douglas Lee, PhD, reported at FDA's Sept. 13-14 International Workshop on Clearance of TSE Agents from Blood Products.

You may also be interested in...



Panel Recommends Human Dura Mater Reclassification Into Class II

Processed human dura mater should be classified as a Class II device, FDA's Neurological Devices Panel unanimously (7-0) recommended Sept. 17 at a meeting in Gaithersburg, Maryland.

Pfizer Holds Number One Spot And Takeda Breaks The Top 10

Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future. 

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel